Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesChemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated with Paclitaxel
The Journal of Pain, 07/14/09
Reyes-Gibby CC et al. - Results showed that 64% experienced CIPN during paclitaxel treatment. Follow-up survey data revealed that 27% of those with CIPN were subsequently diagnosed with NP. Logistic regression analyses showed that those who had experienced CIPN were 3 times more likely to develop NP, which persisted in the multivariate logistic model. In addition, NP patients reported twice as many visits to their health care provider and had taken more prescription and over-the-counter medications for pain than those without NP. The results of this study confirm that CIPN is a predictor of NP, suggesting that survivors treated with paclitaxel should be regularly monitored for NP beyond treatment.
Related Articles
A phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
Journal of Clinical Oncology, 10/19/09
Relevance Score: 94%
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic NSCLC
Annals of Oncology, 10/19/09
Relevance Score: 92%
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Annals of Oncology, 11/10/09
Relevance Score: 89%
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 10/29/09
Relevance Score: 88%
Weekly paclitaxel and cisplatin in the treatment of elderly advanced non-small cell lung cancer
Chinese Journal of Lung Cancer, 10/27/09
Relevance Score: 88%
Today in Adverse Drug Reactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
Core Evidence, 12/11/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Complications and side-effects of foam sclerotherapy
Phlebology, 12/09/09
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors
Chemotherapy, 12/11/09
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
The Lancet - Early Online Publication, 12/11/09
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin
Cancer Chemotherapy and Pharmacology, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor